An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Biotricity Inc. (BTCY) launches a groundbreaking cardiac monitoring pilot program in collaboration with a prestigious hospital group comprising 9 hospitals and 10 clinics. The program aims to optimize patient interaction protocols and streamline data collection processes, showcasing the impact of Biotricity's technology suite. This initiative follows strategic partnerships with leading Group Purchasing Organizations (GPOs) totaling $264 billion, providing access to 90% of hospitals nationwide. The CEO, Dr. Waqaas Al-Siddiq, emphasizes the transformative potential of their solutions in redefining disease profiling, patient management, and preventative care methodologies. With a focus on a $35 billion market opportunity, Biotricity is positioned as an innovative leader in healthcare.
Biotricity Inc. (BTCY) lancia un innovativo programma pilota di monitoraggio cardiaco in collaborazione con un prestigioso gruppo ospedaliero che comprende 9 ospedali e 10 cliniche. Il programma mira a ottimizzare i protocolli di interazione con i pazienti e a razionalizzare i processi di raccolta dati, evidenziando l'impatto della suite tecnologica di Biotricity. Questa iniziativa segue le partnership strategiche con le principali Organizzazioni di Acquisto di Gruppo (GPO) per un totale di 264 miliardi di dollari, fornendo accesso al 90% degli ospedali a livello nazionale. Il CEO, Dr. Waqaas Al-Siddiq, sottolinea il potenziale trasformativo delle loro soluzioni nel ridefinire il profilo delle malattie, la gestione dei pazienti e le metodologie di cura preventiva. Con un focus su un'opportunità di mercato da 35 miliardi di dollari, Biotricity si posiziona come leader innovativo nel settore sanitario.
Biotricity Inc. (BTCY) lanza un programa piloto pionero de monitoreo cardíaco en colaboración con un prestigioso grupo hospitalario que incluye 9 hospitales y 10 clínicas. El programa tiene como objetivo optimizar los protocolos de interacción con los pacientes y agilizar los procesos de recolección de datos, mostrando el impacto del conjunto de tecnologías de Biotricity. Esta iniciativa sigue a asociaciones estratégicas con las principales Organizaciones de Compra Grupal (GPO) por un total de 264 mil millones de dólares, proporcionando acceso al 90% de los hospitales a nivel nacional. El CEO, Dr. Waqaas Al-Siddiq, enfatiza el potencial transformador de sus soluciones en la redefinición del perfil de enfermedades, la gestión de pacientes y las metodologías de atención preventiva. Con un enfoque en una oportunidad de mercado de 35 mil millones de dólares, Biotricity se posiciona como un líder innovador en el cuidado de la salud.
바이오티시티 인크(Biotricity Inc., BTCY)가 9개의 병원과 10개의 클리닉을 포함하는 명망 높은 병원 그룹과 협력하여 혁신적인 심장 모니터링 파일럿 프로그램을 시작합니다. 이 프로그램은 환자 상호작용 프로토콜을 최적화하고 데이터 수집 과정을 간소화하여 바이오티시티의 기술 스위트의 영향을 보여주는 것을 목표로 합니다. 이번 이니셔티브는 전국 병원의 90%에 대한 접근을 제공하는 총 2640억 달러에 달하는 주요 그룹 구매 조직(GPO)과의 전략적 파트너십에 이어집니다. CEO인 와카스 알-시디크 박사(Dr. Waqaas Al-Siddiq)는 그들의 솔루션이 질병 프로파일링, 환자 관리 및 예방 치료 방법론을 재정의하는 데 있어 변혁적인 잠재력을 강조합니다. 350억 달러 시장 기회에 중점을 두고 바이오티시티는 헬스케어 분야의 혁신적인 리더로 자리매김하고 있습니다.
Biotricity Inc. (BTCY) lance un programme pilote de surveillance cardiaque révolutionnaire en collaboration avec un groupe hospitalier prestigieux comprenant 9 hôpitaux et 10 cliniques. Le programme vise à optimiser les protocoles d'interaction avec les patients et à rationaliser les processus de collecte de données, en mettant en évidence l'impact de la suite technologique de Biotricity. Cette initiative fait suite à des partenariats stratégiques avec les principales Organisations d'Achat Groupé (GPO) représentant un total de 264 milliards de dollars, offrant un accès à 90% des hôpitaux à l'échelle nationale. Le PDG, Dr. Waqaas Al-Siddiq, souligne le potentiel transformateur de leurs solutions dans la redéfinition du profilage des maladies, la gestion des patients et les méthodologies de soins préventifs. Avec un focus sur une opportunité de marché de 35 milliards de dollars, Biotricity se positionne en tant que leader innovant dans le secteur de la santé.
Biotricity Inc. (BTCY) startet ein bahnbrechendes Pilotprogramm zur Herzüberwachung in Zusammenarbeit mit einer renommierten Krankenhausgruppe, die 9 Krankenhäuser und 10 Kliniken umfasst. Das Programm zielt darauf ab, die Protokolle für die Patienteninteraktion zu optimieren und die Datenerfassungsprozesse zu straffen, um die Auswirkungen der Technologie-Suite von Biotricity zu demonstrieren. Diese Initiative folgt auf strategische Partnerschaften mit führenden Group Purchasing Organizations (GPOs) im Wert von insgesamt 264 Milliarden Dollar, die Zugang zu 90% der landesweiten Krankenhäuser bieten. Der CEO, Dr. Waqaas Al-Siddiq, betont das transformative Potenzial ihrer Lösungen bei der Neudefinition von Krankheitsprofilen, Patientenmanagement und Methoden der präventiven Pflege. Mit einem Fokus auf eine Marktmöglichkeit von 35 Milliarden Dollar positioniert sich Biotricity als innovativer Marktführer im Gesundheitswesen.
Positive
None.
Negative
None.
REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes. This cardiac monitoring pilot program is poised to showcase the revolutionary impact of Biotricity's technology suite.
This collaboration comes at the heels of another recent pilot, shortly after Biotricity established strategic partnerships with leading GPOs, which wield immense purchasing power, totaling $264 billion. The collective GPO partnerships Biotricity has established provide a staggering 90% of hospitals nationwide with access to its technology. Leveraging this in conjunction with its innovative TaaS model, Biotricity ensures that advanced medical care is accessible to all, dismantling barriers to healthcare accessibility.
"Securing this pilot study not only validates the transformative potential of our solutions but also signifies a significant step towards redefining disease profiling, patient management, and preventative care methodologies," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "Our strategic partnerships with GPOs [Group Purchasing Organizations] were key to launching this major cardiac monitoring pilot program and underscores our commitment to advancing the healthcare industry."
With its sights set on a $35 billion market opportunity, Biotricity stands as a beacon of innovation and is primed to transform the future of healthcare. Investors are encouraged to explore Biotricity's robust revenue trajectory and comprehensive suite of medical diagnostic and consumer healthcare technologies at www.biotricity.com/investors.
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to several risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
What is the latest initiative announced by Biotricity Inc. (BTCY)?
Biotricity Inc. (BTCY) has launched a cardiac monitoring pilot program in collaboration with a prestigious hospital group comprising 9 hospitals and 10 clinics.
What are the key objectives of the cardiac monitoring pilot program by Biotricity Inc. (BTCY)?
The program aims to optimize patient interaction protocols and streamline data collection processes, showcasing the impact of Biotricity's technology suite.
What recent partnerships have Biotricity Inc. (BTCY) established?
Biotricity Inc. (BTCY) has established strategic partnerships with leading Group Purchasing Organizations (GPOs) totaling $264 billion, providing access to 90% of hospitals nationwide.
Who is the CEO of Biotricity Inc. (BTCY) and what is their view on the pilot program?
Dr. Waqaas Al-Siddiq, the founder and CEO of Biotricity, emphasizes the transformative potential of their solutions in redefining disease profiling, patient management, and preventative care methodologies.
What market opportunity is Biotricity Inc. (BTCY) focusing on?
Biotricity Inc. (BTCY) has its sights set on a $35 billion market opportunity, positioning itself as an innovative leader in healthcare.
biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. biotricity’s premier product is bioflux, an ecg monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients. biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution, which empowers users to self-manage chronic conditions. biolife helps users make lifestyle changes by combining medically relevant ecg data with social media interactivity and a lifestyle log. biotricity’s r&d continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. the company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.
